Table 3.
eGFR, mL/minute/1.73 m2 | Regadenoson | Placebo | ||
---|---|---|---|---|
n | Mean ± SD | n | Mean ± SD | |
All subjects | ||||
Baseline | 330 | 41.96 ± 11.89 | 167 | 41.26 ± 11.27 |
Change from baseline | 325 | −0.43 ± 5.99 | 165 | −0.34 ± 4.37 |
Stage 3 CKD | ||||
Baseline | 284 | 44.69 ± 10.29 | 142 | 44.20 ± 9.06 |
Change from baseline | 281 | −0.60 ± 6.36 | 140 | −0.46 ± 4.62 |
Stage 4 CKD | ||||
Baseline | 46 | 25.09 ± 5.50 | 25 | 24.56 ± 7.34 |
Change from baseline | 44 | 0.66 ± 2.47 | 25 | 0.32 ± 2.50 |
eGFR, Estimated glomerular filtration rate; SD, standard deviation.